Abstract:Abstract Acute myeloid leukemia (AML) is one of the most aggressive forms of hematological malignancies with a low overall 5-year survival rate (< 26%). The mainstay of treatment for AML includes chemotherapy, but the response of a subset of patients to current treatment options remains poor. Thus, new therapeutic approaches are desperately needed. AML often arises from somatic mutations in chromatin regulators that result in uncontrolled proliferation and a block of differentiation in myeloid progenitor cells. As such, investigation of the role and molecular mechanism of chromatin regulator in AML is being actively pursued. Previously, we discovered the eleven-nineteen-leukemia (ENL) protein, a chromatin “reader” and transcription co-activator, as an unrecognized requirement for the survival of AML. We developed a potent and orally bioavailable small-molecule inhibitor of ENL, which displaces ENL from chromatin and blocks AML progression. Hotspot mutations have been found in ENL YEATS domains, both in Wilms tumor and in leukemia, and these mutations confer a gain of condensation property, leading to aberrant gene activation. However, the impact of ENL mutation on tumorigenesis is largely unknown. The over-arching goal of this project is to explore the impact of the hyper-activated ENL pathway (ENL mutation) in AML. Results from this project will elucidate how newly discovered chromatin reader mutations drive tumorigenesis and offer new biology insights that will facilitate both basic mechanistic studies and clinical studies. Citation Format: Yiman Liu, Qinglan Li, Sylvia Tang, Chujie Gong, Liling Wan. Investigating the impact of hotspot mutations in a chromatin reader on leukemogenesis. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4754.

Comprehensive insights into AML relapse: genetic mutations, clonal evolution, and clinical outcomes

Recent progress in AML with recurrent genetic abnormalities

Pursuing dynamics of minimal residual leukemic subclones in relapsed and refractory acute myeloid leukemia during conventional therapy

Convergent epigenetic evolution drives relapse in acute myeloid leukemia

Clonal Evolution and Devolution after Chemotherapy in Adult Acute Myelogenous Leukemia

Identification of Cell Type-Specific Effects of DNMT3A Mutations on Relapse in Acute Myeloid Leukemia

Advances in pathogenesis research and challenges in treatment development for acute myeloid leukemia

Outcomes and genetic dynamics of acute myeloid leukemia at first relapse

Current and emerging molecular and epigenetic disease entities in acute myeloid leukemia and a critical assessment of their therapeutic modalities

Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer?

Early drivers of clonal hematopoiesis shape the evolutionary trajectories of de novo acute myeloid leukemia

The genesis and evolution of acute myeloid leukemia stem cells in the microenvironment: From biology to therapeutic targeting

Early drivers of clonal hematopoiesis shape the evolutionary trajectories of acute myeloid leukemia

Molecular Mutations and Their Cooccurrences in Cytogenetically Normal Acute Myeloid Leukemia

Abstract 4754: Investigating the impact of hotspot mutations in a chromatin reader on leukemogenesis

Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML)

Cytogenetics and genomics of acute myeloid leukemia

The epigenetic state of the cell of origin defines mechanisms of leukemogenesis

Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence

Single cell RNA sequencing of AML initiating cells reveals RNA-based evolution during disease progression

Multi-omics analysis of longitudinal patient samples reveals the molecular mechanism of AML progression